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Abstract 1 
Purpose: To estimate the specificity of the Guided Progression Analysis (GPA, Carl Zeiss Meditec, 2 
CA), in individual glaucoma patients.  3 
Design: Observational cohort study. 4 
Participants: Thirty patients with open-angle glaucoma. 5 
Methods: In 30 patients with open-angle glaucoma, one eye (median Mean Deviation [MD], -2.5 6 
dB, interquartile range -4.4 to -1.3 dB) was tested 12 times over 3 months (Humphrey Field 7 
Analyzer, Carl Zeiss Meditec; SITA Standard, 24-2). “Possible progression” and “likely progression” 8 
were determined with the Guided Progression Analysis (GPA). These analyses were repeated after 9 
the order of the tests had been randomly re-arranged (1000 unique permutations).  10 
Main Outcome Measures: Rate of false-positive alerts of “possible progression” and “likely 11 
progression” with the Guided Progression Analysis.   12 
Results:  On average, the specificity of the GPA “likely progression” alert was high—for the entire 13 
sample, the mean rate of false-positive alerts after 10 follow-up tests was 2.6%. With “possible 14 
progression”, the specificity was considerably lower (false-positive rate, 18.5%). Most importantly, 15 
the cumulative rate of false-positive alerts varied substantially among patients, from <1% to 80% 16 
with “possible progression”, and from <0.1% to 20% with “likely progression”. Factors associated 17 
with false-positive alerts were visual field variability (standard deviation of MD, Spearman’s 18 
rho=0.41, p<0.001) and the reliability indices (proportion of false-positive and false-negative 19 
responses, fixation losses, rho>0.31, p≤0.10). 20 
Conclusions: On average, progression criteria currently employed in the GPA have high 21 
specificity, but some patients are much more likely to show false-positive alerts than others. This 22 
must be considered when the GPA is used in clinical practice, where specificity needs to be 23 
controlled for individuals rather than for large groups of patients. 24 
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Introduction 25 
In patients with glaucoma, accurate decisions on visual field progression are a prerequisite of good 26 
clinical management.1, 2 Visual fields have complex properties, and therefore progression is best 27 
judged with the help of software such as the Guided Progression Analysis (GPA) of the Humphrey 28 
Field Analyser (HFA, Carl Zeiss Meditec, Dublin, CA). 3 4-6 29 
The GPA compares each test result, point by point, to values from two earlier baseline tests. Points 30 
are highlighted on a probability plot if changes exceed the typical measurement variability derived 31 
from a group of stable glaucoma patients. If such changes occur at 3 or more points, and in 2 32 
consecutive follow-up tests, the GPA raises an alert of “possible progression”; if they occur in 3 33 
consecutive tests an alert of “likely progression” is raised. Criteria similar to “likely progression” 34 
were used in the Early Manifest Glaucoma Trial, and the GPA has subsequently been widely 35 
adopted in clinical practice and research.7, 8 Previous studies have shown that the analysis agrees 36 
reasonably closely with the subjective judgement of expert clinicians,9, 10 and some authors have 37 
used the GPA as a reference standard for functional change in glaucoma.11, 12  38 
Owing to the fundamental role of visual field progression in the clinical management of glaucoma, 39 
it is important to know how often the GPA raises alerts of “possible progression” and “likely 40 
progression” in the absence of genuine change, i.e. false-positives. We previously demonstrated that 41 
the GPA is likely to have high specificity, on average.13 However, the analysis is based on a 42 
statistical model of typical variability inferred from a group of stable patients—it does not take into 43 
account that some patients are more reliable test-takers than others.14 Because the reproducibility of 44 
visual fields varies more than 2-fold between individuals with the same degree of damage (Artes et 45 
al, Invest. Ophthalmol. Vis. Sci. 54: E-Abstract 2630), the limits for significant change of the GPA 46 
are likely to be too wide for patients who are have relatively low variability, and too narrow for 47 
those with relatively larger variability.  48 
In this study, we aim to investigate how the specificity of the GPA varies between individual 49 
patients. For this purpose, we tested a group of patients multiple times, over a short period of time 50 
during which a clinically meaningful change was unlikely to have taken place.  51 
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Methods 52 
Patients 53 
Thirty patients were recruited from the glaucoma clinics at the Queen Elizabeth Health Sciences 54 
Centre in Halifax, Nova Scotia. Inclusion criteria were a clinical diagnosis of open-angle glaucoma, a 55 
Mean Deviation (MD) better than -15.0 dB in at least one eye, absence of ocular or systemic 56 
pathology known to reduce visual field sensitivity, and the ability and willingness to participate for 57 
12 consecutive weekly sessions. All patients were experienced with static automated perimetry and 58 
had performed at least 5 visual field tests before the study started. They had well controlled levels of 59 
intraocular pressure as judged by their physician (MTN). In accordance with the Declaration of 60 
Helsinki, the institutional research ethics board approved the protocol, and all patients gave written 61 
informed consent.  62 
Tests 63 
Patients attended 12 weekly sessions over a period of 3 months. During each session, the study eye 64 
was examined with program 24-2 SITA-Standard of the HFA.  65 
Analysis 66 
Guided Progression Analysis (GPA) 67 
The GPA is based on principles previously described as Glaucoma Change Probability.14 In brief, a 68 
visual field baseline is calculated from the first two tests, and each subsequent test is then compared, 69 
point by point, to this baseline. If the difference in pattern deviation exceeds the retest variability 70 
estimated from a group of stable patients, the corresponding location is flagged on a probability 71 
map by an open triangle. Half-filled and solid triangles signify change on two or three consecutive 72 
follow-up tests, respectively. The GPA gives alerts of “possible progression” and “likely 73 
progression” when there are three or more locations with half-filled or solid triangles, respectively. 74 
  75 
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Permutation 76 
The premise of our study was that a meaningful change was unlikely to have taken place during the 77 
short period of 3 months during which the 12 tests were performed. Under this assumption, a GPA 78 
alert of “possible progression” or “likely progression” in the series of 12 tests could be regarded as a 79 
false-positive event. Furthermore, by assuming that the order of the tests could be treated as 80 
arbitrary, a large number of permutations could be generated from the originally observed series, by 81 
randomly changing the order of the tests in the sequence. In this way, the probability of observing a 82 
false-positive “possible progression” or a “likely progression” alert could be derived specifically for 83 
each individual patient. For each patient, we submitted 1000 permuted series to Carl Zeiss Meditec 84 
who generated the GPA results as they would appear on the instrument’s output.  85 
 86 
Analysis 87 
Individually for each patient, we determined the proportion of series in which at least one alert of 88 
“possible progression” or “likely progression” had been raised, at the 4th through the 12th test, 89 
across the 1000 permuted series. Similarly, we determined the cumulative probability of 90 
encountering at least one “possible progression” or “likely progression” alert in a patient’s series of 91 
12 tests (2 baseline and 10 follow-up tests). Confidence intervals for the mean proportion of false-92 
positive alerts across the group of patients were determined by bootstrap (n=10,000 samples). We 93 
also investigated the association between the cumulative probability of encountering at least one 94 
progression alert after 12 tests (2 baseline and 10 follow-up tests) and the MD, the standard 95 
deviation (SD) of the MD, and to indices of patient reliability (false-positive and false-negative 96 
response errors, fixation losses, averaged across the entire series of 12 tests). All analyses were 97 
performed in the open-source programming language R (R Foundation for Statistical Computing, 98 
Vienna, Austria; http://www.R-project.org; last accessed 20 January 2014). 99 
  100 
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Results 101 
The median age of the patients was 69.1 years (interquartile range [IQR], 64.4 to 70.7 years). 102 
Patients had early to moderate visual field damage (median MD, -2.5 dB, IQR -4.4 to -1.3 dB) as 103 
illustrated in Figure 1 (available at http://aaojournal.org). All patients were experienced test-takers, 104 
and there were no clinically important learning- or practice effects—the mean MD of the 30 105 
patients changed by <0.1 dB between the first and last tests (Fig. 2, (available at 106 
http://aaojournal.org). However, the variability of the MD varied by a factor >3 between patients 107 
(Fig. 3).  108 
The analysis of the randomly re-ordered test results confirmed that, on average, the specificity of 109 
the GPA “likely progression” alert was high—after 10 follow-up tests (12 tests in total, including 110 
the 2 baselines), the mean false-positive alert rate across the 30 patients was 2.6% (95% confidence 111 
interval: 1.2%, 4.4%). The specificity of the “possible progression” alert was considerably lower—112 
after 10 tests the mean false-positive rate was 18.5% (95% confidence interval: 11.5%, 26.5%) (Figs. 113 
4, 5). Most importantly, however, the false-positive rate of the GPA varied substantially between 114 
patients.  In 11 patients (37%), no “likely progression” alerts were detected in any of the 1000 115 
reordered series, and 4 of these patients also did not have a “possible progression” alert. On the 116 
other hand, in one patient 80% of the reordered series contained alerts of “possible progression”, 117 
and 18% contained alerts of “likely progression”.  118 
“Possible progression” and “likely progression” alerts were more closely associated with the patient 119 
reliability indices (false-positive and -negative response errors, fixation losses) and with visual field 120 
variability (SD of MD) than with visual field damage as measured with MD and Pattern Standard 121 
Deviation (PSD). However, none of these associations were sufficiently strong to predict to a useful 122 
level of accuracy in which patients the GPA would be prone to false-positive progression alerts. 123 
(Table 1, Figs. 6, 7; available at http://aaojournal.org).  124 
125 
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Discussion 126 
The aim of our study was to investigate the specificity of the Glaucoma Progression Analysis, i.e. 127 
the likelihood of encountering a “possible progression” or “likely progression” alert in a series of 128 
visual fields in which no meaningful change has taken place. Stable series were established by testing 129 
patients frequently over a short period during which disease progression was unlikely, such that any 130 
GPA progression alert could be regarded as a false-positive event. Under the assumption that the 131 
order of the tests could be randomly exchanged, we were able to estimate the rate of false-positive 132 
GPA progression alerts from a large number of random permutations of the original visual field 133 
series, for each individual patient. 134 
Our results corroborate earlier reports of high average specificity with the GPA13, 15 — after 12 tests, 135 
the average false-positive rate of “likely progression” alerts was <5%. With tests conducted at 136 
intervals of 6 months, a series of 12 tests would translate to approximately 5 years of follow-up, and 137 
this level of specificity appears sufficiently high for most clinical applications. However, the large 138 
variation in the GPA false-positive rates between individual patients confirmed our hypothesis that 139 
some patients are much more prone to show false-positive progression alerts than others. The high 140 
average specificity of the GPA observed in a group of patients does not apply equally to all patients. 141 
The GPA uses a statistical model to establish, point by point, whether the differences between a 142 
follow-up test and two earlier baseline tests exceed the limits of measurement variability typically 143 
observed in patients with glaucoma. This model aims to account for the amount of baseline damage 144 
at individual test locations, for the location within the visual field, and for the overall damage of the 145 
visual field as measured by the MD index.14 The lack of a relationship between the GPA false-146 
positive rate and visual field damage (as measured by MD and PSD, Fig. 6, available at 147 
http://aaojournal.org) indicates that the GPA adequately compensates for the larger threshold 148 
variability in damaged areas of the visual field. However, the level of damage explains less than half 149 
of the variability in visual field measurements.16, 17  Clearly, there are patient-related factors unrelated 150 
to visual field damage that influence variability, for example the ability to sustain attention and to 151 
provide consistent responses. Because the GPA uses the variability estimated from a reference 152 
group of patients, the analysis is overly conservative (i.e., highly specific, but less sensitive) in 153 
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patients who are highly reliable test-takers, and not sufficiently conservative (i.e., more sensitive, but 154 
less specific) in patients with relatively larger between-test variability.  155 
While there were statistically significant relationships between overall visual field variability 156 
(measured by the SD of the MD), the reliability indices (false-positive and false-negative response 157 
errors, and fixation losses), and the likelihood of false-positive GPA progression alerts, these 158 
associations were too weak to be practically useful for predicting in which patients the GPA is most 159 
likely to produce false-positive progression alerts (Fig. 6, 7; available at http://aaojournal.org). 160 
One alternative to the Glaucoma Change Probability model of the GPA is pointwise linear 161 
regression (PLR), a method that has been widely discussed elsewhere.18-20 PLR establishes statistical 162 
significance of change at individual visual field locations by least-squares linear regression of 163 
sensitivity (or deviation) over time. Other statistical models for deriving rate of change and its 164 
statistical significance at single test locations have also been proposed.21-23 Common to all of these 165 
techniques is that the patient’s own variability is estimated, obviating the need to rely on variability 166 
estimates from other patients. O’Leary et al. have recently introduced a method (Permutation of 167 
Pointwise Linear Regression, PoPLR) in which the statistical significance of deterioration over the 168 
entire visual field is derived solely from random re-ordering (permutation) of the individual patient’s 169 
data, without reference to population-based reference values.24 This method provides an 170 
individualised statistical test of the null hypothesis that there is no negative change at any visual field 171 
location, removing any between-patient variation in specificity. We believe that this method may 172 
provide a useful alternative to the Glaucoma Change Probability model of the GPA, particularly 173 
when more than 5 tests are available for analysis and when specificity needs to be controlled at the 174 
level of the individual patient, as it must be in clinical practice.  175 
Two assumptions of our study are a) that visual fields obtained over a short period of time are 176 
representative of those obtained over a longer period, and b) that any re-ordered sequence of tests 177 
could have occurred with the same likelihood as the originally observed sequence. It is likely that 178 
visual field data violate both assumptions. Variability, for example, may be higher in the long term 179 
than observed during the 12-week period of our study, and the differences between two tests 180 
obtained one after the other may be smaller than between tests at the start and the end of the 181 
sequence (serial correlation). However, while these violations may affect our estimates of specificity, 182 
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they are unlikely to have a substantial effect on the finding that the specificity of the GPA varies 183 
considerably between patients. 184 
In summary, we have shown that the GPA criterion of “likely progression” has high specificity on 185 
average, but that some patients are much more prone to false-positive alerts than others. Rather 186 
than discouraging clinicians from using the GPA, we hope that this report helps to avoid false-187 
positive decisions on progression in patients with larger-than-average variability and frequent 188 
response errors. 189 
 190 
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